Chinese Biotechs Hit By Price Cuts Write Down $84.8m
Executive Summary
From BeiGene and Innovent to Zai Lab, companies have written down amounts equivalent to 44% of their combined product revenues in the fourth quarter of 2021 to compensate distributors after reimbursement prices for oncology drugs were slashed sharply by the government related to inclusion in a national reimbursement list.